Company Overview and News

 
Vereit: Making Sense Of Current Prices

2018-04-17 seekingalpha
I have been a long-term follower of VEREIT (Vereit) (NYSE:VER), going back to an investment when it was called American Realty Capital Properties. I started writing about the stock back in 2016 when I named it my mid-cap stock pick for the year in an article published on Seeking Alpha here. Back then I asserted that the $8.48 price was due for improvement as management was not receiving credit for the progress it had made in turning the company around.
Upvote Downvote

 
The MnM Portfolio, Mar 2018 - A Leaner And Meaner Portfolio

2018-04-11 seekingalpha
This month’s article marks the thirty-seventh installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
Upvote Downvote

1
Our High Yield, Value REIT Portfolio Designed For Outperformance

2018-04-05 seekingalpha
The ~9.22% yield is fully supported with a lower FFO payout ratio than the average REIT.
Upvote Downvote

 
CareTrust Has A Wide Margin Of Safety

2018-04-02 seekingalpha
Having too much exposure to one tenant can be devastating and that’s why most REITs work hard to reduce reliance on one source of income.
Upvote Downvote

 
Beware Of These 'Sucker Yields': The Bracket Buster Edition

2018-03-22 seekingalpha
Finding the right REIT at the right price – with a margin for safety against unknown market risk – is the ultimate goal.
Upvote Downvote

 
VER / VEREIT, Inc. DEFA14A

2018-03-21 sec.gov
Document UNITED STATES <
Upvote Downvote

 
VER / VEREIT, Inc. DEF 14A

2018-03-21 sec.gov
Document UNITED STATES
Upvote Downvote

1
Why I Just Added This 7.8%-Yielding Commercial Property REIT To My Income Portfolio

2018-03-14 seekingalpha
I bought VEREIT, Inc. for my high-yield income portfolio this week as I believe the REIT makes an exceptional value proposition.
Upvote Downvote

2
Vereit: Price Vs. Risk

2018-03-13 seekingalpha
Guidance for AFFO is flat in 2018 and suggests it will be flat again in 2019.
Upvote Downvote

1
Up To 12.3% Yields - Why Invest In This High Yield Asset Class

2018-03-13 seekingalpha
We consider the “net lease property” asset class to be one of the strongest of all in generating high returns relative to the conservative risk profile.
Upvote Downvote

 
The MnM Portfolio, February 2018 - Employer Contributions Boost The Portfolio By $11k

2018-03-13 seekingalpha
This month’s article marks the thirty-sixth installment in my ongoing series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
Upvote Downvote

 
American Assets' Chairman Has Bought $54 Million In Stock Since May

2018-03-12 valuewalk
American Assets Trust, Inc (NYSE: AAT) Chairman and CEO has been buying large quantities of stock since May. These transactions are notable considering the stock is trading at such a low valuation. Value investors may want to take a closer look at the company.
Upvote Downvote

1
Spirit Realty: Special Situation REIT With 30% Return Potential

2018-03-07 seekingalpha
Spirit Realty is a very high quality REIT trading at a steep discount to peers due to issues related to a single tenant representing 8% of rent.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 02917T104